Coldstream Capital Management Inc. Has $6.21 Million Stake in Medtronic PLC $MDT

Coldstream Capital Management Inc. raised its stake in shares of Medtronic PLC (NYSE:MDT) by 24.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,151 shares of the medical technology company’s stock after buying an additional 12,694 shares during the period. Coldstream Capital Management Inc.’s holdings in Medtronic were worth $6,206,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Corundum Trust Company INC acquired a new position in shares of Medtronic in the third quarter worth $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the third quarter valued at $29,000. Delos Wealth Advisors LLC purchased a new position in Medtronic in the second quarter valued at about $27,000. Imprint Wealth LLC purchased a new position in Medtronic in the third quarter valued at about $31,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic in the 3rd quarter worth about $33,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is currently owned by insiders.

Medtronic Trading Down 1.4%

NYSE:MDT opened at $87.17 on Thursday. The company’s 50 day moving average is $97.29 and its 200-day moving average is $96.78. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The firm has a market cap of $111.92 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 2.27 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MDT. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Royal Bank Of Canada raised their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Robert W. Baird reduced their target price on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. JPMorgan Chase & Co. decreased their target price on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Finally, Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).